Crafter’s Companion Improves Fulfilment Efficiency by 25% and Reduces Error Rate to Less Than 1% with Descartes Ecommerce Warehouse Solution 29-08-2023, 17:45

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed 21-09-2025, 09:15

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) 21-09-2024, 15:10